Organovo Holdings Inc
NASDAQ:ONVO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Organovo Holdings Inc
NASDAQ:ONVO
|
US |
|
P
|
Premiere Island Power REIT Corp
XPHS:PREIT
|
PH |
|
S
|
Sansheng Intellectual Education Technology Co Ltd
SZSE:300282
|
CN |
|
RioCan Real Estate Investment Trust
TSX:REI.UN
|
CA |
|
Sebang Global Battery Co Ltd
KRX:004490
|
KR |
|
CLIQ Digital AG
XETRA:CLIQ
|
DE |
|
CMC Metals Ltd
XTSX:CMB
|
CA |
|
S
|
Smartcraft ASA
OSE:SMCRT
|
NO |
|
D
|
Danang Housing Investment Development JSC
VN:NDN
|
VN |
|
E
|
Everest Securities JSC
VN:EVS
|
VN |
|
Samsung Biologics Co Ltd
KRX:207940
|
KR |
|
Sensera Ltd
ASX:SE1
|
AU |
Organovo Holdings Inc
Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2013-08-02. The firm is focused on building high fidelity, three-dimensional (3D) tissues that recapitulate key aspects of human disease. The firm is targeting the intestine and has ongoing 3D tissue developments in Ulcerative colitis (UC) and Crohn's disease (CD). The firm uses its platform technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. NovoGen Bioprinters can dispense pure hydrogel formulations and also serve as important components of company's tissue prototyping and manufacturing platform. The firm also intends to use its bioprinting platform as well as 3D technologies to treat its target diseases.
Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2013-08-02. The firm is focused on building high fidelity, three-dimensional (3D) tissues that recapitulate key aspects of human disease. The firm is targeting the intestine and has ongoing 3D tissue developments in Ulcerative colitis (UC) and Crohn's disease (CD). The firm uses its platform technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. NovoGen Bioprinters can dispense pure hydrogel formulations and also serve as important components of company's tissue prototyping and manufacturing platform. The firm also intends to use its bioprinting platform as well as 3D technologies to treat its target diseases.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
